The GREENFUND - we're buying the dip, big time, and here's why., page-65

First 65 Last

Share
Profile

Follow
hotcongo

3,689 Posts.

596

24/10/19

23:58

Post #: 41058905
Share

Originally posted by Southoz ↑

Mmm … its complicated; because it can be both. A trial pharmacist can “manufacture” an investigational product by compounding; mixing up a brew.

But more commonplace and in a trial like the one here - yes “manufacture” would encompass the dolling of individual portions and the labelling. The site takes over with respect to stock management, storage, preparation and dispensing.

But look take a step back here.

There is always 1% of truth to these company dog ate my homework type explanations to failed trial results. So sure there might have been minor variation in vehicle quality but nothing to the extent that explains that placebo response.

But lets say it was true. What would happen. Well basically it’s a runway train scenario.

The PIs have no choice but to notify their IRB of this protocol violation (which this is) that has essentially negated the scientific value of the US component of this trial. Many US participants have essentially wasted their time taking part in this trial.

The IRB has no choice but to inform the FDA. The FDA would inspect those manufacturing sites. Given the difficulty BOT seem to be having in getting on top of what has happened the record keeping quality control must be terrible. The FDA would close them down.

Why this big drama – because of the safety risk.

A child experiences an unusual adverse health event. The mother takes him to ED. She informs the clinician the child is on a clinical trial for a new acne treatment. She doesn’t know what it is exactly or whether the child is in the placebo or active arm.

The treating clinician will ring the trial pharmacist / Study Coordinator who will break the blind to inform the clinician what treatment the child is receiving. Good news the Study Coordinator says … it’s the placebo. A vehicle … completely harmless. Thanks says the treating doctor we can rule that out. But it turns out the placebo was really an active. What a potential disaster.

This just can’t be allowed to happen.

So have the PIs / BOT informed the US IRBs of this stuff-up? Has the FDA been notified? If not - why not? If this manufacturing stuff-up is true and the PIs and BOT haven’t notified the IRB / FDA they would be in breach of a dozen US regulatory laws.

They haven’t because the manufacturing variation (or problems) is in reality inconsequential. It is only in BOTs head that this caused the trial to fail. No-one else thinks this because if they did then they would have reported it because they don’t want to go to jail.

Expand

Thanks for your answer, Southoz.

could you please email me on another matter? I would really welcome your opinion on something that has been bugging me for months.
my email is [email protected]

thanks!

BOT Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 95 more messages in this thread...

First 65 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 28.3¢		Change -0.008(2.59%)		Mkt cap ! $456.7M

Open	High	Low	Value	Volume
30.0¢	30.0¢	28.3¢	$719.9K	2.491M

Buyers (Bids)

No.	Vol.	Price($)
22	738782	28.0¢

Sellers (Offers)

Price($)	Vol.	No.
28.5¢	488823	9

View Market Depth

No.	Vol.	Price($)
21	713961	0.280
26	1383862	0.275
30	731680	0.270
9	177662	0.265
20	673131	0.260

Price($)	Vol.	No.
0.285	492823	10
0.290	306054	9
0.295	322621	6
0.300	1091960	17
0.305	361420	12

Last trade - 11.59am 04/06/2024 (20 minute delay)


Last 28.5¢		Change -0.008 ( 2.83 %)
Open	High	Low	Volume
29.5¢	29.5¢	28.0¢	1365760
Last updated 12.18pm 04/06/2024 ?

BOT (ASX) Chart

The GREENFUND - we're buying the dip, big time, and here's why., page-65

Featured News

Daily ASX Market Open: Commodity prices to weigh | June 4, 2024

Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa

Kincora secures untested porphyry project Wongarbon in prime territory

Infini boosts WA uranium holdings with Bellah Bore East acquisition

Immutep targets $100m for lung cancer drug trial tests

Buyers (Bids)

Sellers (Offers)

Featured News

The GREENFUND - we're buying the dip, big time, and here's why., page-65

Featured News

Top Stories

Daily ASX Market Open: Commodity prices to weigh | June 4, 2024

Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa

Kincora secures untested porphyry project Wongarbon in prime territory

Infini boosts WA uranium holdings with Bellah Bore East acquisition

Immutep targets $100m for lung cancer drug trial tests

Buyers (Bids)

Sellers (Offers)

Featured News